Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma This is one of the most important articles of the year. It discusses the results of the first small ICT-107 vaccine trial. The key outcome: "At a median follow-up of 40.1 months, six of 16 newly diagnosed GBM patients showed no evidence of tumor recurrence. " Notice the Acknowledgments section: This study was supported by funding from Musella Foundation For Brain Tumor Research & Information, Inc. and ImmunoCellular Therapeutics Ltd. This confirms that we (The Musella Foundation) seek out and fund the best research. Not only did we fund this project, but we also funded the early development on one of the targets of the vaccine. This is a perfect example of how important YOUR donations are. People always ask me if making donations can make a difference. This proves it.

Suicide Gene killing deadly brain cancer: Nappanee woman in national study This is one of the more promising new treatments out there... I am keeping an eye on it.

Cigarette smoking: a risk factor for postoperative morbidity and 1-year mortality following craniotomy for tumor resection. This study shows that smokers do worse after brain tumor surgery, and that quitting helps.

David S. Zocchi Foundation events This is an announcement about events at the Monmouth Medical Center, NJ. Nothing to do with the Musella Foundation but may be of interest to you!